(Q33387732)

26 July 2017

1 reference

title

Obstetrical complications associated with abnormal maternal serum markers analytes (English)

1 reference

26 July 2017

10

Anne Summers

1 reference

26 July 2017

3

François Audibert

1 reference

26 July 2017

Alain Gagnon

1

1 reference

26 July 2017

R Douglas Wilson

2

1 reference

26 July 2017

Victoria M Allen

4

1 reference

26 July 2017

Claire Blight

5

1 reference

26 July 2017

Jo-Ann Brock

6

1 reference

26 July 2017

Valerie A Désilets

7

1 reference

26 July 2017

Jo-Ann Johnson

8

1 reference

26 July 2017

Sylvie Langlois

9

1 reference

26 July 2017

Philip Wyatt

11

1 reference

26 July 2017

Society of Obstetricians and Gynaecologists of Canada Genetics Committee

12

1 reference

26 July 2017

publication date

1 October 2008

1 reference

Journal of Obstetrics and Gynaecology Canada

26 July 2017

published in

1 reference

26 July 2017

volume

30

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

918-949

1 reference

Prenatal screening for fetal aneuploidy

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Placental pathology at term associated with elevated midtrimester maternal serum alpha-fetoprotein concentration

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Second-trimester maternal serum alpha-fetoprotein (MSAFP) is elevated in women with adverse pregnancy outcome associated with inherited thrombophilias

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Factors associated with fetal demise in fetal echogenic bowel

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Mid-trimester triple test levels in early and late onset severe pre-eclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Outcomes in patients with unusually high maternal serum alpha-fetoprotein levels

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Risks associated with an elevated maternal serum a-fetoprotein level

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Prognostic significance of unexplained elevated amniotic fluid alpha-fetoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Association of maternal serum alpha-fetoprotein with persistent placenta previa

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Midtrimester hemoperitoneum caused by placenta percreta in association with elevated maternal serum alpha-fetoprotein level

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Effect of hypoxia on trophoblast in organ culture. A morphologic and autoradiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Placental mosaicism is associated with unexplained second-trimester elevation of MShCG levels, but not with elevation of MSAFP levels

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Pathologic findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Elevated midtrimester maternal serum hCG in chromosomally normal pregnancies is associated with preeclampsia and velamentous umbilical cord insertion

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Elevated second-trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Midtrimester triple test levels in women with severe preeclampsia and HELLP syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Mid-trimester placentation assessment in high-risk pregnancies using maternal serum screening and uterine artery Doppler

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Isolated low second-trimester maternal serum β-human chorionic gonadotropin is not associated with adverse pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Clinical significance of low levels of second-trimester maternal serum human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Low maternal serum concentrations of human chorionic gonadotropin as part of the triple test screening: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Pregnancy-associated plasma protein A, free human chorionic gonadotrophin and nuchal translucency as predictors of miscarriage

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The prediction of adverse pregnancy outcome using low unconjugated estriol in the second trimester of pregnancy without risk of Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Quad screen as a predictor of adverse pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Low maternal serum unconjugated estriol during prenatal screening as an indication of placental steroid sulfatase deficiency and X-linked ichthyosis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Pregnancy outcome for women with very low levels of maternal serum unconjugated estriol on second-trimester screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Very low maternal serum unconjugated estriol and prenatal diagnosis of steroid sulfatase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Low or absent unconjugated estriol in pregnancy: an indicator for steroid sulfatase deficiency detectable by fluorescence in situ hybridization and biochemical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Prenatal diagnosis of congenital adrenal hypoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Differential diagnosis and management of very low second trimester maternal serum unconjugated estriol levels, with special emphasis on the diagnosis of X-linked ichthyosis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Prenatal diagnosis of Smith-Lemli-Opitz syndrome in a pregnancy with low maternal serum oestriol and a sex-reversed fetus

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Serum inhibin A levels in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

High maternal serum inhibin A levels following the loss of one fetus in a twin pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal serum and amniotic fluid inhibin A levels in women who subsequently develop severe preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Improved early prediction of pre-eclampsia by combining second-trimester maternal serum inhibin-A and uterine artery Doppler.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Adverse pregnancy outcome after a false-positive screen for Down syndrome using multiple markers

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Significance of a false-positive trisomy 18 multiple-marker screening test.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Double-positive maternal serum screening results for down syndrome and open neural tube defects: An indicator for fetal structural or chromosomal abnormalities and adverse obstetric outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Elevated alpha-fetoprotein and human chorionic gonadotropin as a marker for placental trisomy 16 in the second trimester?

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Abnormal levels of maternal serum human chorionic gonadotropin and alpha-fetoprotein in the second trimester: relation to fetal weight and preterm delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal serum inhibin-A levels in twin pregnancies: implications for screening for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Multiple marker screening for Down syndrome in twin pregnancies

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Unexplained elevated maternal serum alpha-fetoprotein levels and pregnancy outcome in twins

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Midtrimester maternal serum screening after multifetal pregnancy reduction in pregnancies conceived by in vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal serum analyte levels after first-trimester multifetal pregnancy reduction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Does a “vanishing twin” affect first-trimester biochemistry in Down syndrome risk assessment?

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Biochemical screening for Down syndrome in pregnancies following renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Elevated second-trimester maternal serum hCG in patients undergoing haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal serum hCG and alpha-fetoprotein levels in pregnancies conceived after IVF or ICSI with fresh and frozen-thawed embryos

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Serum free beta-HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal serum α-fetoprotein and human chorionic gonadotropin levels in women with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Is maternal serum triple screening a better predictor of Down syndrome in female than in male fetuses?

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Risk of abnormal triple screen for Down syndrome is significantly higher in patients with female fetuses

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The influence of fetal sex in screening for Down syndrome in the second trimester using AFP and free beta-hCG.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal serum alpha-fetoprotein and altitude

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The relationship between maternal serum alpha-fetoprotein and maternal haemoglobin

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal serum inhibin-A in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)?

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Elevated maternal midtrimester serum free beta-human chorionic gonadotropin levels in vegetarian pregnancies that cause increased false-positive Down syndrome screening results

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Elevated maternal serum alpha-fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Ultrasound diagnosis of severe thrombotic placental damage in the second trimester: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Second-trimester prediction of severe placental complications in women with combined elevations in alpha-fetoprotein and human chorionic gonadotrophin

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Uterine artery Doppler velocimetry in the detection of adverse obstetric outcomes in women with unexplained elevated maternal serum alpha-fetoprotein levels.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Uterine artery Doppler velocimetry in the prediction of adverse obstetric outcomes in unexplained MSAFP elevations

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The role of Doppler velocimetry in the structurally normal second-trimester fetus with elevated levels of maternal serum alpha-fetoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Perinatal outcome in pregnancies with a positive serum screening for Down's syndrome due to elevated levels of free β-human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The clinical value of combining maternal serum screening and uterine artery Doppler in prediction of adverse pregnancy outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Screening for pre-eclampsia by using maternal serum inhibin A, activin A, human chorionic gonadotropin, unconjugated estriol, and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The association of abnormal alpha-fetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome?

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Unexplained elevated maternal serum alpha-fetoprotein: what is the appropriate follow-up?

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Doppler velocimetry of the umbilical artery as a predictor of pregnancy outcome in pregnancies characterized by elevated maternal serum alpha-fetoprotein and normal amniotic fluid alpha-fetoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Doppler velocimetry of the umbilical artery as a predictor of outcome in pregnancies characterized by elevated beta-subunit human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotropin levels

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Mid-trimester levels of alphafetoprotein in the screening of low birthweight.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Prediction of smallness for gestational age by maternal serum human chorionic gonadotropin levels and by uterine artery Doppler study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The value of elevated second-trimester beta-human chorionic gonadotropin in predicting development of preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Second trimester serum free beta human chorionic gonadotrophin levels as a predictor of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Analysis of mid-trimester corticotrophin-releasing hormone and alpha-fetoprotein concentrations for predicting pre-eclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Correlation between second trimester maternal serum inhibin-A and human chorionic gonadotrophin for the prediction of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal and biochemical predictors of spontaneous preterm birth among nulliparous women: a systematic analysis in relation to the degree of prematurity

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Multiple marker second trimester serum screening for pre-eclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Unexplained elevated maternal serum alpha-fetoprotein in singleton pregnancies as a predictor of fetal risk

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Elevated levels of midtrimester maternal serum alpha-fetoprotein are associated with preterm delivery but not with fetal growth retardation

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Elevated hCG as an isolated finding during the second trimester biochemical screen: genetic, ultrasonic, and perinatal significance

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Obstetric outcomes in women with elevated maternal serum human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Elevated second-trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Outcome of pregnancies with elevation of both maternal serum alpha-fetoprotein and human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

The detection of non-immune hydrops through second-trimester maternal serum screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

Maternal Serum Triple Analyte Screening and Adverse Pregnancy Outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932973-5

7 January 2021

10.1016/S1701-2163(16)32973-5

Identifiers

DOI

0 references

1 reference